Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Environ Res ; 234: 116579, 2023 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-37423372

RESUMEN

The effect of fly ash type on the sustainability of concrete mixtures has yet to be quantified. This study aims to assess the environmental impacts of low calcium oxide (CaO) and high CaO fly ash in mass concrete mixtures from Thailand. The study analyzed 27 concrete mixtures with varying percentages of fly ash as a cement replacement (0%, 25%, and 50%) for 30 MPa, 35 MPa, and 40 MPa compressive strengths at specified design ages of 28 and 56 days. Sources of fly ash have been located between 190 km and 600 km away from batching plants. The environmental impacts were assessed using SimaPro 9.3 software. The global warming potential of concrete is reduced by 22-30.6% and 44-51.4% when fly ash, regardless of type, is used at 25% and 50%, respectively, in comparison with pure cement concrete. High CaO fly ash has more environmental benefits than low CaO fly ash when utilized as a cement substitute. The reduction in environmental burden was most significant for the midpoint categories of mineral resource scarcity (10.2%), global warming potential (8.8%), and water consumption (8.2%) for the 40 MPa, 56-day design with 50% fly ash replacement. The longer design age (56 days) for fly ash concrete showed better environmental performance. However, long-distance transport significantly affects ionizing radiation and ecotoxicity indicators for terrestrial, marine, and freshwater environments. Furthermore, the results show that a high cement replacement level (50%) may not always have a reduced environmental impact on mass concrete when considering long-distance transportation. The critical distance calculated based on ecotoxicity indicators was shorter than those calculated using global warming potential. The results of this study can provide insights for developing policies to increase concrete sustainability using different types of fly ash.


Asunto(s)
Ceniza del Carbón , Materiales de Construcción , Óxidos , Compuestos de Calcio
2.
Sci Rep ; 13(1): 18254, 2023 Oct 25.
Artículo en Inglés | MEDLINE | ID: mdl-37880405

RESUMEN

Fly ash has been widely used as a cement substitute to improve the sustainability of concrete. Although the advantages of fly ash have been extensively documented, there is a gap in understanding why its use in mass concrete applications remains low in some countries, such as the Philippines. Thus, this work aims to understand the issues that impede waste utilization, particularly fly ash in the concrete construction industry, quantify the impact of the current practice, and identify opportunities for sustainable fly ash utilization. Endpoint impact analysis was conducted through the life cycle using SimaPro 9.3 to quantify the impacts on human health, ecosystem, and resources of 31 concrete mixtures of low, normal, and high strength design with 0 to 20% fly ash as cement replacement. In-depth, semi-structured interviews with key stakeholders were undertaken to determine the institutional, economic, social, and technological challenges related to the utilization of waste materials in large-scale concrete construction. More than 90% of the total impact of concrete contributes to damage to human health, primarily caused by global warming and fine particulate matter. The use of fly ash at 20% replacement by weight of cement benefits resources more significantly than human health and the ecosystem. The use of chemical admixture to improve strength has a significant impact on resources. High fly ash replacement for normal and high-strength concrete has a greater reduction in all endpoint categories than for low-strength design. Recommendations are proposed to maximize the beneficial impact of using fly ash in the concrete industry.

3.
Materials (Basel) ; 9(5)2016 May 19.
Artículo en Inglés | MEDLINE | ID: mdl-28773511

RESUMEN

Pore structure, tortuosity and permeability are considered key properties of porous materials such as cement pastes to understand their long-term durability performance. Three-dimensional image analysis techniques were used in this study to quantify pore size, effective porosity, tortuosity, and permeability from the X-ray computed tomography (CT) images of deteriorated pastes that were subjected to accelerated leaching test. X-ray microtomography is a noninvasive three-dimensional (3D) imaging technique which has been recently gaining attention for material characterization. Coupled with 3D image analysis, the digitized pore can be extracted and computational simulation can be applied to the pore network to measure relevant microstructure and transport properties. At a spatial resolution of 0.50 µm, the effective porosity (ψe) was found to be in the range of 0.04 to 0.33. The characteristic pore size (d) using a local thickness algorithm was found to be in the range of 3 to 7 µm. The geometric tortuosity (τg) based on a 3D random walk simulation in the percolating pore space was found to be in the range of 2.00 to 7.45. The water permeability values (K) using US NIST Permeability Stokes Solver range from an order of magnitudes of 10-14 to 10-17 m². Indications suggest that as effective porosity increases, the geometric tortuosity increases and the permeability decreases. Correlation among these microstructure and transport parameters is also presented in this study.

4.
J Biochem ; 151(2): 129-37, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22023799

RESUMEN

The antibiotic heliquinomycin inhibited cellular DNA replication at IC(50) of 2.5 µM without affecting level of chromatin-bound MCM4 and without activating the DNA replication stress checkpoint system, suggesting that heliquinomycin perturbs DNA replication mainly by inhibiting the activity of replicative DNA helicase that unwinds DNA duplex at replication forks. Among the DNA helicases involved in DNA replication, DNA helicase B was inhibited by heliquinomycin at IC(50) of 4.3 µM and RECQL4 helicase at IC(50) of 14 µM; these values are higher than that of MCM4/6/7 helicase (2.5 µM). These results suggest that heliquinomycin mainly targets actions of the replicative DNA helicases. Gel-retardation experiment indicates that heliquinomycin binds to single-stranded DNA. The single-stranded DNA-binding ability of MCM4/6/7 was affected in the presence of heliquinomycin. The data suggest that heliquinomycin inhibits the DNA helicase activity of MCM4/6/7 complex by stabilizing its interaction with single-stranded DNA.


Asunto(s)
Antibacterianos/metabolismo , ADN Helicasas/antagonistas & inhibidores , ADN de Cadena Simple/metabolismo , Antibacterianos/química , Benzoquinonas/química , Benzoquinonas/metabolismo , Sitios de Unión , Proteínas de Ciclo Celular/antagonistas & inhibidores , Proteínas de Ciclo Celular/química , Proteínas de Ciclo Celular/metabolismo , ADN Helicasas/química , ADN Helicasas/metabolismo , Replicación del ADN/efectos de los fármacos , ADN de Cadena Simple/química , Proteínas de Unión al ADN/antagonistas & inhibidores , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/metabolismo , Ensayo de Cambio de Movilidad Electroforética , Células HeLa , Humanos , Componente 4 del Complejo de Mantenimiento de Minicromosoma , Componente 6 del Complejo de Mantenimiento de Minicromosoma , Componente 7 del Complejo de Mantenimiento de Minicromosoma , Complejos Multiproteicos/antagonistas & inhibidores , Complejos Multiproteicos/metabolismo , Proteínas Nucleares/antagonistas & inhibidores , Proteínas Nucleares/química , Proteínas Nucleares/metabolismo , Compuestos de Espiro/química , Compuestos de Espiro/metabolismo
5.
FEBS J ; 276(12): 3382-91, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19438708

RESUMEN

The antibiotic heliquinomycin, which inhibits cellular DNA replication at a half-maximal inhibitory concentration (IC(50)) of 1.4-4 microM, was found to inhibit the DNA helicase activity of the human minichromosome maintenance (MCM) 4/6/7 complex at an IC(50) value of 2.4 microM. In contrast, 14 microM heliquinomycin did not inhibit significantly either the DNA helicase activity of the SV40 T antigen and Werner protein or the oligonucleotide displacement activity of human replication protein A. At IC(50) values of 25 and 6.5 microM, heliquinomycin inhibited the RNA priming and DNA polymerization activities, respectively, of human DNA polymerase-alpha/primase. Thus, of the enzymes studied, the MCM4/6/7 complex was the most sensitive to heliquinomycin; this suggests that MCM helicase is one of the main targets of heliquinomycin in vivo. It was observed that heliquinomycin did not inhibit the ATPase activity of the MCM4/6/7 complex to a great extent in the absence of single-stranded DNA. In contrast, heliquinomycin at an IC(50) value of 5.2 microM inhibited the ATPase activity of the MCM4/6/7 complex in the presence of single-stranded DNA. This suggests that heliquinomycin interferes with the interaction of the MCM4/6/7 complex with single-stranded DNA.


Asunto(s)
Proteínas de Ciclo Celular/metabolismo , ADN Helicasas/antagonistas & inhibidores , Proteínas de Unión al ADN/metabolismo , Proteínas Nucleares/metabolismo , Adenosina Trifosfatasas/antagonistas & inhibidores , Adenosina Trifosfatasas/metabolismo , Benzoquinonas/farmacología , Transporte Biológico/efectos de los fármacos , Bromodesoxiuridina/metabolismo , ADN Helicasas/metabolismo , ADN Polimerasa I/antagonistas & inhibidores , ADN Polimerasa I/metabolismo , ADN Primasa/antagonistas & inhibidores , ADN Primasa/metabolismo , Relación Dosis-Respuesta a Droga , Exodesoxirribonucleasas/antagonistas & inhibidores , Exodesoxirribonucleasas/metabolismo , Células HeLa , Humanos , Componente 4 del Complejo de Mantenimiento de Minicromosoma , Componente 6 del Complejo de Mantenimiento de Minicromosoma , Componente 7 del Complejo de Mantenimiento de Minicromosoma , Complejos Multiproteicos/metabolismo , Unión Proteica/efectos de los fármacos , ARN/genética , ARN/metabolismo , RecQ Helicasas/antagonistas & inhibidores , RecQ Helicasas/metabolismo , Proteína de Replicación A/metabolismo , Compuestos de Espiro/farmacología , Helicasa del Síndrome de Werner
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA